Compound blood pressure reducing pharmaceutical composition, compound blood pressure reducing pharmaceutical preparation and purpose ofcompound blood pressure reducing pharmaceutical preparation

A technology of pharmaceutical preparations and compositions, applied in the field of compound antihypertensive drug compositions, can solve the problems of severe side effects and high cost of combined antihypertensive drugs, achieve rapid onset of action, reduce stroke and cardiovascular events, and side effects The effect of low incidence

Pending Publication Date: 2020-02-07
北京市石景山区高血压联盟研究所
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Therefore, the problem to be solved by the present invention is to overcome the high cost of combined antihypertensive drugs in the prior art and the defects of serious side effects, thereby providing a novel compound anti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound blood pressure reducing pharmaceutical composition, compound blood pressure reducing pharmaceutical preparation and purpose ofcompound blood pressure reducing pharmaceutical preparation
  • Compound blood pressure reducing pharmaceutical composition, compound blood pressure reducing pharmaceutical preparation and purpose ofcompound blood pressure reducing pharmaceutical preparation
  • Compound blood pressure reducing pharmaceutical composition, compound blood pressure reducing pharmaceutical preparation and purpose ofcompound blood pressure reducing pharmaceutical preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The compound antihypertensive pharmaceutical composition in the present embodiment comprises the following components in each preparation unit:

[0056] Amlodipine 1.0 mg; amiloride 20.0 mg; hydrochlorothiazide 50.0 mg, the rest is pharmaceutically acceptable carrier starch, and the preparation is an ordinary tablet.

Embodiment 2

[0058] The compound antihypertensive pharmaceutical composition in the present embodiment comprises the following components in each preparation unit:

[0059] Amlodipine 10.0 mg; amiloride 5.0 mg; hydrochlorothiazide 50.0 mg, the rest is pharmaceutically acceptable carrier starch, and the preparation is an ordinary tablet.

Embodiment 3

[0061] The compound antihypertensive pharmaceutical composition in the present embodiment comprises the following components in each preparation unit:

[0062] Amlodipine 5.0 mg; amiloride 10.0 mg; hydrochlorothiazide 50.0 mg, the rest is pharmaceutically acceptable carrier starch, and the preparation is an ordinary tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound blood pressure reducing pharmaceutical composition. The compound blood pressure reducing pharmaceutical composition comprises the following components of amlodipineor pharmaceutical salts thereof, amiloride or an inorganic acid salt or an organic acid salt of the amiloride, and hydrochlorothiazide or an inorganic acid salt or an organic acid salt of the hydrochlorothiazide. According to the compound blood pressure reducing pharmaceutical composition provided by the invention, the medication dosage of single medicines can be reduced, and the number of medicines practically taken by a patient can be reduced, so that side reactions of medicines can be reduced, and the compliance that the patient takes medicines can be increased.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound antihypertensive drug composition and its application. Background technique [0002] Cardiovascular and cerebrovascular diseases have become the first cause of death among Chinese residents. Hypertension is the main factor leading to stroke, coronary heart disease, congestive heart failure and other cardiovascular diseases. A large number of domestic and foreign clinical trials have confirmed that lowering the blood pressure level of hypertensive patients can significantly reduce the incidence of cardiovascular and cerebrovascular diseases and disability rate and mortality. The latest epidemiological data show that more than 240 million adults in my country suffer from high blood pressure. How to effectively control the blood pressure of hypertensive populations to prevent stroke and cardiovascular events is a major public health problem currently facing our country [0003]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4422A61K31/4965A61K31/549A61P9/12A61P9/10A61P9/04A61P9/00
CPCA61K9/209A61K9/2054A61K31/4422A61K31/549A61K31/4965A61P9/10A61P9/04A61P9/00A61P9/12A61K2300/00
Inventor 胡爱华周宪梁陆培培张宇清王文刘力生
Owner 北京市石景山区高血压联盟研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap